Abstract:Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly prolonged progression-free survival (PFS) in patients with advanced non-small-cell lung cancer. We undertook FASTACT-2, a phase 3 study in a similar patient population.Methods In this phase 3 trial, patients with untreated stage IIIB/IV non-small-cell lung cancer were randomly assigned in a 1: 1 ratio by use of an interactive internet response system with minimisation algorithm (stratified by disease stage, tumour histology, smoking status, and chemotherapy regimen) to receive six cycles of gemcitabine (1250 mg/m(2) on days 1 and 8, intravenously) plus platinum (carboplatin 5 x area under the curve or cisplatin 75 mg/m(2) on day 1, intravenously) with intercalated erlotinib (150 mg/day on days 15-28, orally; chemotherapy plus erlotinib) or placebo orally (chemotherapy plus placebo) every 4 weeks. With the exception of an independent group responsible for monitoring data and safety monitoring board, everyone outside the interactive internet response system company was masked to treatment allocation. Patients continued to receive erlotinib or placebo until progression or unacceptable toxicity or death, and all patients in the placebo group were offered second-line erlotinib at the time of progression. The primary endpoint was PFS in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT00883779.Findings From April 29, 2009, to Sept 9, 2010, 451 patients were randomly assigned to chemotherapy plus erlotinib (n=226) or chemotherapy plus placebo (n=225). PFS was significantly prolonged with chemotherapy plus erlotinib versus chemotherapy plus placebo (median PFS 7.6 months [95% CI 7.2-8.3], vs 6.0 months [5.6-7.1], hazard ratio [HR] 0.57 [0.47-0.69]; p<0.0001). Median overall survival for patients in the chemotherapy plus erlotinib and chemotherapy plus placebo groups was 18.3 months (16.3-20.8) and 15.2 months (12.7-17.5), respectively (HR 0.79 [0.64-0.99]; p=0.0420). Treatment benefit was noted only in patients with an activating EGFR gene mutation (median PFS 16.8 months [12.9-20.4] vs 6.9 months [5.3-7.6], HR 0.25 [0.16-0.39]; p<0.0001; median overall survival 31.4 months [22.2-undefined], vs 20.6 months [14.2-26.9], HR 0.48 [0.27-0.84]; p=0.0092). Serious adverse events were reported by 76 (34%) of 222 patients in the chemotherapy plus placebo group and 69 (31%) of 226 in the chemotherapy plus erlotinib group. The most common grade 3 or greater adverse events were neutropenia (65 [29%] patients and 55 [25%], respectively), thrombocytopenia (32 [14%] and 31 [14%], respectively), and anaemia (26 [12%] and 21 [9%], respectively).Interpretation Intercalated chemotherapy and erlotinib is a viable first-line option for patients with non-small-cell lung cancer with EGFR mutation-positive disease or selected patients with unknown EGFR mutation status.

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)

A Randomized, Double-Blind, Phase III Study Comparing Two Doses of Erlotinib for Second-Line Treatment of Current Smokers with Advanced Non-Small-cell Lung Cancer (Currents)

Sunitinib Plus Erlotinib for the Treatment of Advanced/Metastatic Non–Small-Cell Lung Cancer: A Lead-In Study

The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients with Advanced Non-Small-Cell Lung Cancer.

Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small-cell Lung Cancer.

Efficacy and Safety Results from CurrentS, a Double-Blind, Randomized, Phase III Study of Second-Line Erlotinib (150 Mg Versus 300 Mg) in Current Smokers with Advanced Non-Small Cell Lung Cancer (NSCLC).

A Randomized Placebo-Controlled Phase III Study of Intercalated Erlotinib with Gemcitabine/platinum in First-Line Advanced Non-Small Cell Lung Cancer (NSCLC): FASTACT-II.

Preliminary Results Of Randomized Phase Iii Study Comparing Efficacy And Safety Of First-Line Erlotinib Versus Carboplatin (Cbdca) Plus Gemcitabine (Gem) In Chinese Advanced Non-Small Cell Lung Cancer (Nsclc) Patients (Pts) With Egfr-Activating Mutations (Optimal)

Clinical Efficacy of Erlotinib in Patients Previously Treated for Advanced Non‐small Cell Lung Cancer

Third-line Treatment: A Randomized, Double-Blind, Placebo-Controlled Phase III ALTER-0303 Study—efficacy and Safety of Anlotinib Treatment in Patients with Refractory Advanced NSCLC.

Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer

Intercalated Combination of Chemotherapy and Erlotinib for Patients with Advanced Stage Non-Small-cell Lung Cancer (FASTACT-2): a Randomised, Double-Blind Trial

Erlotinib in the Second/Third Line Treatment of Patients with Advanced Non-small Cell Lung Cancer

Three-arm Randomised Controlled Phase 2 Study Comparing Pemetrexed and Erlotinib to Either Pemetrexed or Erlotinib Alone As Second-Line Treatment for Never-Smokers with Non-Squamous Non-Small Cell Lung Cancer

A Multicenter, Randomized, Open-Label, Phase Ii Trial of Erlotinib Versus Etoposide Plus Cisplatin with Concurrent Radiotherapy in Unresectable Stage Iii Non-Small Cell Lung Cancer (nsclc) with Epidermal Growth Factor Receptor (egfr) Activating Mutation.

Erlotinib As Second-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and Asymptomatic Brain Metastases: A Phase Ii Study (Ctong-0803)

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

Intercalated Combination of Chemotherapy and Erlotinib for Stage IIIA Non-Small-cell Lung Cancer: a Multicenter, Open-Label, Single-Arm, Phase II Study

A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.

Sunitinib in Patients with Refractory NSCLC: Primary Results from China.

Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer